Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27912903 | 0.98 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL344569 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL344797 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1279722 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL227336 | 0.84 | HPGD (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL447646 | 0.84 | HPGD (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16142409 | 0.83 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL8479449 | 0.82 | GPR119 (0.57) | HPGDRECQLEPHX1GPR119KDM4E | |
| SCHEMBL6915624 | 0.82 | NR1H2 (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17109787 | 0.82 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108219182-B | Preparation method of thermal expansion microspheres | 上海略发化工科技有限公司 | 2020-11-24 | — | — | CN | claimed |
| EP-0578080-B1 | 3,9-disubstituted-spiro (5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same | SIGMA TAU IND FARMACEUTI (IT) | 1997-04-23 | — | — | EP | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4688779-A2 | NOVEL COMPOUNDS AND USES THEREOF | Acelink Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2026-01-20 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| WO-2025109540-A1 | MACROCYCLIC COMPOUNDS AS KIF18A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-30 | — | — | WO | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| EP-0799223-B1 | PIPERIDINEACETIC ACID DERIVATIVES USEFUL AS FIBRINOGEN ANTAGONIST AGENT | GLAXO GROUP LTD (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0912555-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| US-5861414-A | INHIBITING BLOOD PLATELET AGGREGATION FOR ANTITHROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| WO-1997049699-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049698-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| EP-0799223-A1 | PIPERIDINEACETIC ACID DERIVATIVES USEFUL AS FIBRINOGEN ANTAGONIST AGENT | GLAXO GROUP LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996041803-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996020192-A1 | PIPERIDINEACETIC ACID DERIVATIVES USEFUL AS FIBRINOGEN ANTAGONIST AGENT | GLAXO GROUP LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | HPGD 3307/4885RECQL 108/4885EPHX1 1860/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | HPGD 4353/4885RECQL 768/4885EPHX1 2304/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | HPGD 1489/4885RECQL 161/4885EPHX1 941/4885 |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | SLC10A6, SLCO4C1, SLCO2A1 | HPGD 2378/4885RECQL 2936/4885EPHX1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.